Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
PR Newswire
NEW YORK, Sept. 9, 2026
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Picard Medical caused the company to misrepresent or fail to disclose that (1) Picard was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Picard's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price.
If you currently own PMI and purchased prior to September 2, 2025 please contact J Sophia Anne Silayan by email at sophiaanne@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
SOURCE Kuehn Law, PLLC
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
33 Undervalued Stocks to Buy Before the Market Shifts Again
The Thrilling 37
United States